We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Optibrium Logo


Optibrium provides elegant software solutions for small molecule design, optimization and data analysis, to guide decisions and improve efficiency in drug discovery.

Latest Optibrium Content

AI written on a computer chip.
Product News

Optibrium Launches a Metabolism Prediction Software Platform Tailored to DMPK Scientists

Semeta™ offers high sensitivity and superior precision for the prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discovery.
Advert for the new Idea Tracker.
Product News

Optibrium Enables Collaborative Design in Its StarDrop Platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking. The software promotes collaboration within and across teams for more cohesive workflows
A computer chip that resembles a brain.
Product News

Optibrium’s Quantum Mechanics and Machine Learning Methods Predict Routes of Drug Metabolism

Peer-reviewed study published in Xenobiotica describes an innovative new method that predicts the routes and products of Phase I and II metabolism with high sensitivity and greater precision than other approaches.
An individual sitting at a table with their laptop open.
Product News

Optibrium Introduces Cloud-Based Version of StarDrop Drug Discovery Platform

Optibrium, announced that its drug discovery platform, StarDrop, is now also available in the cloud environment.
An assortment of different pills.
Product News

Optibrium Releases Powerful Metabolism Prediction Capability in Next Generation StarDrop Software

Backed by six years’ research, the new StarDrop Metabolism module combines quantum mechanics and machine learning to better predict the metabolic fate of drug candidates.
An assortment of pills sitting in the palm of a hand.
Product News

Optibrium Acquires BioPharmics LLC, Expanding Its 3D Drug Design and Visualisation Offering

Optibrium, announced the acquisition of BioPharmics LLC, expanding its 3D drug design and modelling offering. Bringing decades of experience in computational chemistry and biology.
The Optibrium and PostEra logos.
Product News

Optibrium and PostEra Collaborate To Integrate AI Drug Discovery Solutions

Optibrium and PostEra have announced a collaboration to integrate Optibrium’s StarDrop platform with PostEra’s Manifold software.
Steve Yemm and Dr. Matthew Segall, CCO and CEO of Optibrium.
Product News

Optibrium Appoints Steve Yemm as Chief Commercial Officer

Optibrium has announced the appointment of Steve Yemm as Chief Commercial Officer.
Optibrium Strengthens Global AI Drug Discovery Software Operations With Three Key Appointments content piece image
Product News

Optibrium Strengthens Global AI Drug Discovery Software Operations With Three Key Appointments

Optibrium has announced three key appointments: Michelle Harrison as head of strategic marketing, Chris Khoury as associate director of business development, and Imran Ghauri as business development manager.
Optibrium Receives Further Investment From Kester Capital content piece image
Product News

Optibrium Receives Further Investment From Kester Capital

Optibrium™ has announced it has secured further investment from existing investors Kester Capital, a leading UK mid-market private equity firm.